Scholarlink

Background <p>Brain tumors are the most challenging malignancies. The existing investigational and treatment modalities have a few drawbacks with high rate of recurrence / residual tumoral tissue. Positron Emitting Tomography combined with computed tomography (PET-CT) is a widely used imaging modality for oncology and non-oncological purposes with fluorine-18-floruodeoxyglucose (18&#xa0;F-FDG) being the most familiar radiotracer. Physiological uptake of FDG in brain parenchyma makes it a challenging task to currently delineate the residual/ recurrent brain tumors which brings us to investigate new radiotracers.</p> Objective <p>The purpose of present study is to identify the role of 18 fluoride labelled Prostate Specific Membrane Antigen (PSMA) in residual recurrent brain malignancies and compared the PSMA PET-CT scan with standard conventional imaging in same purpose.</p> Methods <p>This was a prospective study and patients were enrolled after underwent treatment (surgery and /or concurrent chemoradiotherapy). In order to detection of the residual recurrent disease, 18&#xa0;F PSMA PET-CT as well as conventional imaging modalities were performed. We calculated the diagnostic performance of the PSMA PET-CT and also compared with standard conventional imaging modalities.</p> Results <p>Thirty-one patients were included in the study. Out of 31 patients, 23 (~ 74.2%) patients were positive on PSMA PET-CT scan and 18 (~ 58.06%) were on conventional imaging (CI) for residual recurrent mitotic disease. The calculated sensitivity, specificity, PPV, NPV and diagnostic yields for PSMA PET-CT and CI were 96%, 88%, 96%, 88% and 93.5% and 83%, 50%, 83%, 50% and 74.2% respectively. In our study, among 31 patients, 22 patients underwent MRI imaging in form of convention imaging and calculated sensitivity, specificity, PPV, NPV and diagnostic yields for MRI was 81%, 42.85%, 76.5%, 50% and 77.3% respectively. Among these 22 patients, MRI with PSMA PET-CT scan was discordant in 7 patients (27.3%).</p> Conclusion <p>18&#xa0;F-PSMA PET-CT imaging has higher diagnostic yield then existing conventional diagnostic modalities with capability to rule out extracranial lesions and inherent-potential of being utilised as theragnostic moiety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Is 18F-PSMA PET/CT a reliable imaging modality to evaluate the status of recurrent/residual brain tumors in post-treatment patients?

  • 期刊论文

  • 发表日期：

    2025年7月31日

查看全文
  • Tarun Kumar Jain,
  • Mansha Vohra,
  • Bhawani Shanker sharma,
  • Anushree loyal,
  • Priya Sharma,
  • Patel Meet,
  • Shikha dhal,
  • Vineet Mishra,
  • Jitendra Singh Verma,
  • Surabhi Tyagi,
  • Hemant Malhotra

摘要

Background

Brain tumors are the most challenging malignancies. The existing investigational and treatment modalities have a few drawbacks with high rate of recurrence / residual tumoral tissue. Positron Emitting Tomography combined with computed tomography (PET-CT) is a widely used imaging modality for oncology and non-oncological purposes with fluorine-18-floruodeoxyglucose (18 F-FDG) being the most familiar radiotracer. Physiological uptake of FDG in brain parenchyma makes it a challenging task to currently delineate the residual/ recurrent brain tumors which brings us to investigate new radiotracers.

Objective

The purpose of present study is to identify the role of 18 fluoride labelled Prostate Specific Membrane Antigen (PSMA) in residual recurrent brain malignancies and compared the PSMA PET-CT scan with standard conventional imaging in same purpose.

Methods

This was a prospective study and patients were enrolled after underwent treatment (surgery and /or concurrent chemoradiotherapy). In order to detection of the residual recurrent disease, 18 F PSMA PET-CT as well as conventional imaging modalities were performed. We calculated the diagnostic performance of the PSMA PET-CT and also compared with standard conventional imaging modalities.

Results

Thirty-one patients were included in the study. Out of 31 patients, 23 (~ 74.2%) patients were positive on PSMA PET-CT scan and 18 (~ 58.06%) were on conventional imaging (CI) for residual recurrent mitotic disease. The calculated sensitivity, specificity, PPV, NPV and diagnostic yields for PSMA PET-CT and CI were 96%, 88%, 96%, 88% and 93.5% and 83%, 50%, 83%, 50% and 74.2% respectively. In our study, among 31 patients, 22 patients underwent MRI imaging in form of convention imaging and calculated sensitivity, specificity, PPV, NPV and diagnostic yields for MRI was 81%, 42.85%, 76.5%, 50% and 77.3% respectively. Among these 22 patients, MRI with PSMA PET-CT scan was discordant in 7 patients (27.3%).

Conclusion

18 F-PSMA PET-CT imaging has higher diagnostic yield then existing conventional diagnostic modalities with capability to rule out extracranial lesions and inherent-potential of being utilised as theragnostic moiety.